电影票房

您好,歡迎訪問中山大學腫瘤防治中心官方網站!
職工郵箱 English
院士風采 首席專家 臨床專家 科研學者 客座教授 人才名錄 護理專家
首頁
  • 王樹森

    職務:內科乳腺病區主任
    職稱:主任醫師、醫學博士、博士生導師、乳腺癌內科首席專家
    專長:乳腺癌的綜合治療(內分泌治療、靶向治療、化學治療)
    1.姓名:王樹森
    2.職務:內科乳腺病區主任
    3.職稱:主任醫師、醫學博士、博士生導師、乳腺癌內科首席專家
    4.專長:乳腺癌的綜合治療(內分泌治療、靶向治療、化學治療)
    5.出診時間:星期一上午、星期四上午

    6.學術兼職:
      中國研究型醫院協會乳腺癌專業委員會副主任委員
      中國抗癌協會乳腺癌專業委員會常務委員
      中國臨床腫瘤協會乳腺癌專業委員會常務委員
      中國抗癌協會腫瘤臨床化療專業委員會青委會副主任委員
      國家腫瘤質控中心乳腺癌質控專業委員會委員
      中國乳腺癌篩查與早診早治指南專家委員會委員
      國家衛健委乳腺癌合理用藥指南專家委員會委員
      廣東省胸部腫瘤防治研究會乳腺癌專業委員會主任委員
      廣東省抗癌協會乳腺癌專業委員會副主任委員
      廣東省醫師協會乳腺專科工作委員會副主任委員
      廣東省抗癌協會化療專業委員會副主任委員。

    7.個人簡介:王樹森,中山大學腫瘤醫院乳腺癌單病種首席專家,內科乳腺病區主任,主任醫師,博士生導師。2004年畢業于中山大學,獲腫瘤學博士學位。2010年在Memorial Sloan-Keterring Cancer Center學習。現在主要從事乳腺癌的化療、內分泌治療及靶向治療。參與了“中國抗癌協會乳腺癌診療指南”、“中國臨床腫瘤協會乳腺癌診療指南”、“國家衛健委乳腺癌合理用藥指南”、“中國晚期乳腺癌維持治療專家共識”等多項指南或共識的編寫,并且是其中一部分的執筆人之一或主要執筆人。作為主要研究者主持了多項一、二及三期的臨床研究;承擔國家自然科學基金重點項目、面上項目、廣東省自然科學基金多項,發表SCI論文30余篇。重點研究方向:乳腺癌侵襲轉移的分子機制;節拍化療在乳腺癌治療領域的應用;年輕乳腺癌的基因組學及臨床診治。

    1.姓名:王樹森
    2.職務:內科乳腺病區主任
    3.職稱:主任醫師
    4.專長:乳腺癌的綜合治療(內分泌治療、靶向治療、化學治療)
    5.出診時間:星期一上午、星期四上午

    6.學術兼職:
      中國研究型醫院協會乳腺癌專業委員會副主任委員
      中國抗癌協會乳腺癌專業委員會常務委員
      中國臨床腫瘤協會乳腺癌專業委員會常務委員
      中國抗癌協會腫瘤臨床化療專業委員會青委會副主任委員
      國家腫瘤質控中心乳腺癌質控專業委員會委員
      中國乳腺癌篩查與早診早治指南專家委員會委員
      國家衛健委乳腺癌合理用藥指南專家委員會委員
      廣東省胸部腫瘤防治研究會乳腺癌專業委員會主任委員
      廣東省抗癌協會乳腺癌專業委員會副主任委員
      廣東省醫師協會乳腺專科工作委員會副主任委員
      廣東省抗癌協會化療專業委員會副主任委員。

    7.個人簡介:王樹森,中山大學腫瘤醫院乳腺癌單病種首席專家,內科乳腺病區主任,主任醫師,博士生導師。2004年畢業于中山大學,獲腫瘤學博士學位。2010年在Memorial Sloan-Keterring Cancer Center學習。現在主要從事乳腺癌的化療、內分泌治療及靶向治療。參與了“中國抗癌協會乳腺癌診療指南”、“中國臨床腫瘤協會乳腺癌診療指南”、“國家衛健委乳腺癌合理用藥指南”、“中國晚期乳腺癌維持治療專家共識”等多項指南或共識的編寫,并且是其中一部分的執筆人之一或主要執筆人。作為主要研究者主持了多項一、二及三期的臨床研究;承擔國家自然科學基金重點項目、面上項目、廣東省自然科學基金多項,發表SCI論文30余篇。重點研究方向:乳腺癌侵襲轉移的分子機制;節拍化療在乳腺癌治療領域的應用;年輕乳腺癌的基因組學及臨床診治。

    8.代表性文章、成果:
    1.Tao Qin, Yinduo Zeng, Qianyi Lu, Xinke Zhang, Ge Qin, Qiufan Zheng,Fei Xu,Roujun Peng, Zhongyu Yuan and Shusen Wang. Nomogram Model of LNR Predicts Survival in Premenopausal.Anticancer Research 37:4575-4586(2017).(corresponding author)
    2.Zheng Qiufan,Xia Wen,Lu Qianyi,Hong Ruoxi,Qin Ge,Xu Fei,Qin Tao,Shi Yanxia,Yuan Zhongyu,Wang Shusen. Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis. Breast Cancer Res Treat,2016 Nov;160(2):197-209. (corresponding author)
    3.Tao Qin,Yin-duo Zeng, Ge Qin, Fei Xu, Jia-bin Lu, Wen-feng Fang, Cong Xue, Jian-hua Zhan, Xin-ke Zhang, Qiu-fan Zheng, Rou-jun Peng, Zhong-yu Yuan, Li Zhang, Shu-sen Wang.High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget, 6(32):2015,33972-81.  (corresponding author)
    4.Ge Qin, Fei Xu, Tao Qin, Qiufan Zheng, Dingbo Shi, Wen Xia, Yun Tian, Yanlai Tang, Jingshu Wang, Xiangshen Xiao, Wuguo Deng, Shusen Wang. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway. Oncotarget, Advance Publications 2015,1-15. (corresponding author)
    5.Qiufan Zheng, Fei Xu, Man Nie, Wen Xia, Tao Qin, Ge Qin, Xin An, Cong Xue, Roujun Peng, Zhongyu Yuan, Yanxia Shi, Shusen Wang. Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer. Medicine,2015,94(40):1-9. (corresponding author)
    6.Tao Qin, Zhong-Yu Yuan, Rou-Jun Peng, Bing Bai, Yin-Duo Zeng, Yan-Xia Shi, Xiao-Yu Teng,Dong-Geng Liu, Shu-Sen Wang. Clinicopathologic characteristics and prognostic factorsfor HER2-positive patients with metastatic breastcancer in southern China. Arch Med Sci 2015; 11, 3: 544–550.(corresponding author)
    7.Xiao Y, Wang J, Qin Y, Xuan Y, Jia Y, Hu W, Yu W, Dai M, Li Z, Yi C, Zhao S, Li M, Du S, Cheng W, Xiao X, Chen Y, Wu T, Meng S, Yuan Y, Liu Q, Huang W, Guo W, Wang S, Deng W. Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.Oncotarget. Oncotarget. 2015 Apr 10;6(10):8046-61. (corresponding author)
    8.Fu L, Shi K, Wang J, Chen W, Shi D, Tian Y, Guo W, Yu W, Xiao X, Kang T, Wang S, Huang W, Deng W. TFAP2B overexpression contributes to tumor growth and a poor prognosis of human lung adenocarcinoma through modulation of ERK and VEGF/PEDF signaling. Mol Cancer,2014,13:89  (corresponding author)
    9.Chen W, Qin L, Wang S, Li M, Shi D, Tian Y, Wang J, Fu L, Li Z, Guo W, Yu W, Yuan Y, Kang T, Huang W, Deng W. CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas. Mol Oncol. 2014 May;8(3):704-716  (corresponding author)
    10.ZENG Yin-duo, XU Fei, QIN Tao,YANG Yan-hua, LIAO Yu-ting,Qin Ge,Wang Shu-sen. Toremifene in Postmenopausal Operable Patients with Luminal Subtype of Breast Cancer as Compared with Tamoxifen:A Retrospective Study in China. Chin J Bases Clin General Surg,  2014,21( 5):555-561(corresponding author)
    11.Ma hongmin,Hu lingyu, Wang shusen.Diagnosis and Treatment for Occult Breast Cancer. Chin J Bases Clin General Surg, 2014, 21( 5):544-548(corresponding author) 
    12.Qin T, Yuan ZY, Peng RJ,Zeng YD,Shi YX, Teng XY,Liu DG, Bai B, Wang SS .Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: a retrospective analysis. Curr Oncol,2013, 20(4):1-9  (corresponding author)
    13. Qin T, Yuan ZY, Peng RJ ,Shi YX, Teng XY,Liu DG, Bai B, Wang SS .HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negativebreast cancer patients. Onco Targets and Therapy.2013,6:341-47   (corresponding author)
    14.QIN Tao, YUAN Zhong-yu, PENG Rou-jun, BAI Bing, SHI Yan-xia, TENG Xiao-yu, LIU Dong-geng, WANG Shu-sen. Efficacy and Safety of Toremifene in Young Patients with Luminal Subtype Early Breast Cancer: A Retrospective Study. JOURNAL OF SUN YAT-SEN UNIVERSITY(MEDICAL SCIENCES),2013,34(3):402-406(corresponding author)
    15.Fu ly, Chen WB, Guo W, Wang JS, Tian Y, Shi DB, Zhang XH,Qiu HJ, Xiao XS, Kang TB, Huang WL, Wang SS, Deng WG.Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth. PIOS ONE,2013,8(7):1-13  (corresponding author)
    16.Gu WG, Huang Y, Yuan ZY, Peng RJ, Luo HT, He ZR, Wang SS. ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts. Asian Pac J Cancer Prev. 2013;14(3):1787-90 (corresponding author)
    17.Wangbing Chen, Wei Guo, Mei Li, Dingbo Shi, Yun Tian, Zhenlin Li, Jingshu Wang, Lingyi Fu, Xiangsheng Xiao, Quentin Qiang Liu, Shusen Wang, Wenlin Huang, Wuguo Deng. Upregulation of cleavage and polyadenylation specific factor 4 in lung adenocarcinoma and its critical role for cancer cell survival and proliferation. PLoS One. 2013;8(12):e82728 (corresponding author)
    18.Wang S, Shi Y, Yuan Z, Wang X, Liu D, Peng R, Teng X, Qin T, Peng J, Lin G, Jiang X. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol. 2012,29:547-553 (first author)
    19.He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T. Prognostic value of androgen receptor expression in operable triple negative breast cancer: A retrospective analysis based on a tissue microarray. Med Oncol 2012,29:406-410
    20.Liu D, He J, Yuan Z, Wang S, Peng R, Shi Y, Teng X, Qin T. EGFR expression correlates with decreased disease-free survival in triple negative breast cancer: A retrospective analysis based on a tissue microarray. Med Oncol. 2012,29:401-405
    21.Shi YX, Tan YT, Yuan ZY, Wang SS, Peng RJ, An X, Cao Y, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG. Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer. Med Oncol 2012,29:39-47 
    22.Shi YX, Xia Q, Peng RJ, Yuan ZY, Wang SS, An X, Cao Y, Tan YT, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG, Jiang WQ. Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer. J Cancer Res Clin Oncol. 2012 ,138:705-714
    23.Wang x, Wang SS, Peng RJ, Qin T, Shi YX, Teng xy, Chen wq, Liu DG,  Yuan ZY. Interaction of coping styles and psychological stress on anxious and depressive symptoms in Chinese breast cancer patients. Asian Pacific J Cancer Prev 2012; 13:1645-1649. (IF:1.24)
    24.Peng R, Wang S, Shi Y, Liu D, Teng X, Qin T, Zeng Y, Yuan Z. Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: A retrospective matched case-control study. Breast. 2011; 20: 568-573.(IF:2.089)
    25.Liu DG, Wang SS, Peng RJ, Qin T, Shi YX, Teng XY,  Wang X, Chen WQ, Yuan ZY. Interaction of Social Support and Psychological Stress on Anxiety and Depressive Symptoms in Breast Cancer Patients. Asian Pacific J Cancer Prev 2011; 12:2523-2529. (IF:1.24) 
    26.Bing Bai, Shusen Wang et al. Clinical Features and Survival Analysis of Different  Subtypes of   Patients with Breast Cancer Brain Metastases. Chinese Journal of Cancer, 2010,29(4): 453-461. (corresponding author) 
    27.Qin jianyong Wang shusen,YIN CHUANZHONG The legal and ethic issues in operating medical information service website. JOURNAL OF MEDICAL INFORMATICS,2010,31(8):52-55
    28.Yuan zhongyu,Shusen Wang, et al.  Clinical Characteristics and Prognosis of Triple-Negative Breast Cancer: A Report of 305 Cases. Chinese Journal of Cancer, 2008, 27(6)..
    29.Yuan zhongyu,Shusen Wang, et al. Clinical characteristics and prognosis of different subtypes of breast cancer Chinese Journal of Oncology.  2008 ,30(6):456-61
    30.Fu xiaohong, Wang shusen, Huang yan,el al. Prognostic significance of CD20 expression in Hodgkin and Reed-sternberg cells of classical hodgkin’s lymphoma. Chinesr journal of cancer 2008,27(11):1197-1203
    31.CAO Ya –Bing, WANG Shu-Sen, HUANG Hui-Qiang et al. Primary Breast Lymphoma —A Report of 27 Cases with Literature Review Chinese Journal of Cancer, 2007, 26( 1) : 84- 89
    32.Xiao Jian, Wang Shusen, Huang Yan et al.  Expression of CD117 and PDGFRa in Extranodular NK/T Cell Lymphoma (Nasal Type) .Chinese Journal of Clinical Oncology 2,007 34(11):615-617
    33.QIU Miao-Zhen, XU Fei, WANG Shu-Sen et al. Responses of 109 Adult Soft Tis sue Sarcoma Patients to Chemotherapy .Chinese Journal of Cancer, 2007, 26( 12) : 1344- 1349
    34.Shusen Wang, Zhongzhen Guan, et al. The Significance of EGFR and p-ERK Expression in Nasopharyngeal Carcinoma,Chinese Journal of Oncology.2006,28(1).
    35.Shusen Wang, Zhongzhen Guan, et al. The Significance of c-Fos, and Cyclin-D1 Expression in Nasopharyngeal Carcinoma,Chinese Journal of Clinical Oncology,2005,32,(6)
    36.Shusen Wang, Zhongzhen Guan, et al. In vivo Study of Epidermal Growth Factor Receptor-Selective Tyrosine Kinase Inhibitor Gefitinib on Nasopharyngeal Carcinoma. Chinese Journal of Cancer, 2004,23(11s). 
    37.Yanqun Xiang, Shusen Wang, et al Prognostic Value of Surviving and Living in Nasopharyngeal Carcinoma, The Laryngoscope, 116(1).
    38.Shusen Wang, Zhongzhen Guan, et al. Angiogenesis Modulator and Tumor. Chinese Journal of Medicine.2004, 4(1): 24-29. 
    39.Shusen Wang, Tongyu Lin, et al. Anti-Cancer Therapy Targeting EGFR. Chinese Journal of Cancer Palliative Medicine. 2003,2(4): 239-242. 
    40.Shusen Wang, Wenqi Jiang. Improving the Level of Clinical Study According to Good Clinical Practice. National Medical Journal of China.2003,83(3):179-180. 
    41.Shusen Wang , Ruilin Wang, et al. Study on the Purification of Angiogenesis Inhibitor from Shark Cartilage and its Biological Characteristics. Henan Journal of Oncololgy.1999, 12(3): 179-181. 
    42.Shusen Wang, Lisong Tan, et al. A Study on the Method Using 1H11 Endothelial Cells to Assay Angiogenesis Inhibitor. ACTA Academiae Medicinae Xuzhou. 1998, 18 (3): 176-178. 
    43.Jinchuan Zhang, Shusen Wang, et al. Detecting Tumor Specific Growth Factor in Patients with Chemotherapy. Academiae Medicinae Xuzhou.2001, 21(2): 116-117. 
    44.Desheng liu, Shusen Wang et al. How to Improve the Effect and Safety of Three-Step Method of Analgesia. Chinese Journal of Clinical Oncology and Recovery.1999, 6 (5): 77-79. 


    更新日期:2018年9月19日

訪客通道
員工通道
關注腫瘤醫院
留言建議 ×